BIOGEN INC.
BIIB · XNASCIK 875045fmd_1DA9376KC4PGRZ664PN82EB6NCManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 11,449 | 12,274 | 13,453 | 14,378 | 13,445 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 |
| Cost of revenue | 1,479 | 1,630 | 1,816 | 1,955 | 1,805 | 2,110 | 2,278 | 2,533 | 2,310 | 2,404 |
| Gross profit | 9,970 | 10,644 | 11,637 | 12,423 | 11,639 | 8,872 | 7,895 | 7,302 | 7,366 | 7,486 |
| Realized investment gains (losses) | – | – | – | 50 | 12 | – | – | – | – | – |
| Research and development | 1,973 | 2,254 | 2,597 | 2,281 | 3,991 | 2,501 | 2,231 | 2,445 | 1,980 | 1,779 |
| Selling, general and administrative | 1,947 | 1,934 | 2,106 | 2,375 | 2,505 | 2,674 | 2,404 | 2,550 | 2,404 | 2,434 |
| Operating income | 5,152 | 5,346 | 5,889 | 7,043 | 4,550 | 2,841 | – | – | – | – |
| Interest expense | 260 | 251 | 201 | 187 | 223 | 254 | 247 | 247 | 250 | 268 |
| Interest and investment income | 63 | 79 | 113 | 120 | 42 | 11 | 89 | 277 | 68 | 125 |
| Other non-operating income (expense) | (219) | (217) | 11 | 83 | 497 | (1,096) | 108 | (316) | (344) | (306) |
| Income before taxes | 4,933 | 5,129 | 5,900 | 7,126 | 5,048 | 1,745 | 3,592 | 1,297 | 1,906 | 1,557 |
| Income tax expense | 1,237 | 2,459 | 1,426 | 1,158 | 992 | 53 | 633 | 135 | 274 | 264 |
| Net income from continuing operations | 3,696 | 2,670 | 4,474 | 5,968 | 4,055 | 1,693 | 2,959 | 1,162 | 1,632 | 1,293 |
| Net income | 3,703 | 2,539 | 4,431 | 5,889 | 4,001 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |